Merz lifts aesthetics unit with $600m Ulthera takeover
This article was originally published in Clinica
German pharmaceutical firm Merz is expanding its aesthetics business with the agreed acquisition of Ulthera, a company specializing in non-surgical skin lifting, for up to $600m. The deal would mark Merz’s largest purchase in its history. It also illustrates an increasing interest from pharma companies in aesthetics, following Valeant’s hostile $54bn bid for Botox developer Allergan – the latter has so far resisted its rival’s overtures.